Track topics on Twitter Track topics that are important to you
Johnson & Johnson sought to reassure investors and analysts that lower-priced competition for one of its top-selling products won’t slow a company that posted slightly better-than-expected results in the third quarter.
Original Article: J&J Brushes Off Looming Biosimilar CompetitionNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...